In body composition research, "cutting" refers to protocols targeting fat mass reduction while preserving or increasing lean mass — typically during caloric restriction. Several SARM and non-SARM research compounds are studied in this context, each with distinct mechanisms and evidence profiles.
S-4 (Andarine) was one of the earliest SARMs investigated by GTx Inc. and shows a partial AR agonist profile. What distinguishes S-4 in body composition research is its demonstrated efficacy at relatively low doses in animal models for maintaining lean mass during caloric deficit, alongside bone-density-protective effects. Its partial agonism (compared to the full agonism of LGD-4033 or RAD-140) results in a somewhat milder anabolic stimulus that may be more appropriate for recomposition research.
A notable consideration in S-4 research is the visual side effect observed in some protocols: a yellowish tint in peripheral vision attributed to a metabolite binding to ocular androgen receptors. This appears dose-dependent and reversible upon cessation, but is documented in informal research reports and relevant to protocol design.
SR-9009 is a Rev-ErbA agonist — an entirely different mechanism from SARMs, acting on a nuclear receptor that regulates circadian rhythm and metabolic gene expression. Rev-ErbA activation upregulates genes governing mitochondrial biogenesis, fat oxidation, and glucose metabolism. Preclinical mouse studies demonstrate significantly increased running endurance and reduced fat mass in obese mice over 30 days at twice-daily dosing.
The primary practical challenge with SR-9009 is its very short half-life (~4 hours), which means maintaining steady-state receptor activation requires frequent dosing in research protocols. Its fat-oxidation mechanism operates independently of the androgen receptor, making it non-suppressive and a candidate for stacking with AR-targeting compounds.
Cardarine shifts cellular energy utilisation towards fatty acid oxidation via PPARδ agonism. Human trial data (Sprecher et al., 2007) documents significant HDL improvement and LDL/triglyceride reduction in overweight subjects, consistent with enhanced lipid metabolism. Endurance-enhancing effects in mouse models are substantial. However, GW-501516's carcinogenicity signals in long-term high-dose rodent studies (which led GSK to terminate the programme in 2007) represent an important safety consideration that researchers must review.
S-23 is among the most potent non-steroidal SARMs in preclinical research, demonstrating near-complete testosterone suppression and significant lean mass effects in rat models. Its potential for body composition research during deficit is its high lean mass retention capacity. However, its potent suppression characteristics require careful post-cycle protocol design. Published human data for S-23 is absent.
| Compound | Mechanism | Suppression | Human data |
|---|---|---|---|
| S-4 (Andarine) | Partial AR agonist | Moderate | Limited Phase I |
| SR-9009 | Rev-ErbA agonist | None | Minimal |
| GW-501516 | PPARδ agonist | None | Phase I lipid data |
| S-23 | Full AR agonist | Severe | Preclinical only |
GW-501516 and SR-9009 have the most direct fat-metabolism mechanisms and neither suppresses testosterone, making them useful additions to AR-targeting protocols. Both have limitations: GW-501516's carcinogenicity concern, and SR-9009's short half-life. S-4's partial AR agonism and lean mass preservation make it relevant for recomposition research.
The two compounds act through entirely different mechanisms (Rev-ErbA vs. PPARδ), and their combination is explored in research on the basis that they target different aspects of fat metabolism. Neither suppresses testosterone, simplifying post-cycle considerations in combination protocols.
